Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma | Clinical Trials | Clareo Health

Back to search

COMPLETED

Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma

NCT04200326•AstraZeneca

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Severe Uncontrolled Asthma

Key Dates

Start Date

December 20, 2019

Primary Completion Date

April 9, 2020

Completion Date

April 9, 2020

Last Updated

April 8, 2021

Related Studies

COMPLETEDPhase 3

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405

Severe Uncontrolled Asthma

View study

Sponsors

Lead Sponsor

AstraZeneca

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2021Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions